May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Kundranda Discusses Options for Therapy in 2 HCC Patient Cases
January 19th 2018Madappa Kundranda, MD, PhD, recently discussed the cases of 2 patients with hepatocellular carcinoma (HCC), and the treatment considerations and decisions he would make when treating these patients. Dr. Kundranda, Director of Gastrointestinal Oncology at Banner MD Anderson Cancer Center, Phoenix discussed these cases during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Blood-Based Liquid Biopsy Demonstrates 88% Accuracy in Detecting Colorectal Cancers Early
January 17th 2018A novel circulating tumor cell assay has demonstrated a high accuracy of up to 88% for detecting early-stage colorectal cancer, according to the results of a prospective study from Taiwan released ahead of a presentation at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California. The study marks the first to show a high sensitivity for detecting precancerous lesions, as prior studies tended to identify later-stage CRCs.
Read More
Neoadjuvant Chemoradiotherapy Does Not Improve HRQOL in Esophageal Cancer
January 16th 2018In results from the phase III CROSS trial reported in the <em>Journal of Clinical Oncology, </em>neoadjuvant chemoradiotherapy failed to lower postoperative health-related quality of life compared with surgery alone for patients with esophageal or junctional cancer.<br />
Read More
The Influence of Mutational Status in Intrahepatic Cholangiocarcinoma
January 15th 2018Jesper B. Andersen, MSc, PhD, discusses a study that shows using a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma can characterize divergent cancer programs and drug vulnerabilities.
Read More
Asian Patients With mCRC See Improved Survival With TAS-102
January 12th 2018According to findings from the phase III TERRA trial published in the <em>Journal of Clinical Oncology, </em>previously treated Asian patients with metastatic colorectal cancer saw a significant survival benefit with TAS-102 (trifluridine and tipiracil; Lonsurf) compared with placebo.
Read More
Kulke Appointed Chief of Hematology/Oncology at BUMC
January 12th 2018Boston University Medical Center has announced that Matthew Kulke, MD, will serve as its chief of the Section of Hematology/Oncology in the Department of Medicine, effective March 1, 2018. Kulke will also obtain the roles of deputy director of the BU-BMC Cancer Center, medical director of the Clinical Cancer Center at BMC, and the Zoltan Kohn Professor of Medicine at the Boston University School of Medicine.
Read More
Hochster Joins Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
January 12th 2018Howard S. Hochster, MD, an internationally recognized leader in the development of cancer clinical trials, gastrointestinal oncology, and early phase cancer drugs, has joined Rutgers Cancer Institute of New Jersey as associate director for clinical research and chief of gastrointestinal medical oncology.
Read More
Immunotherapy Progress in the Treatment of CRC
January 6th 2018John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the progress that has been made with immunotherapy in the treatment of colorectal cancer.
Watch
Clinical Trials Key to Expanding Novel Treatment Options in Metastatic CRC
December 22nd 2017Shubham Pant, MD, discusses therapeutic options for patients with metastatic CRC, while stressing the importance of clinical trials as an avenue to establish more novel treatment decisions in this setting.
Read More
When to Order Next-Generation Sequencing for a Patient With Metastatic Colon Cancer
December 22nd 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses when to order next-generation sequencing for a patient with metastatic colon cancer.
Watch
Kim Discusses Treatment Considerations for Patients With Pancreatic Cancer
December 16th 2017George P. Kim, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic pancreatic cancer. Kim, a medical oncologist at 21st Century Oncology in Jacksonville, Florida, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Exciting Response Rates Seen in Updates Findings of bb2121 in Multiple Myeloma
December 13th 2017Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission. <br />
Read More
Venook on Treatment Recommendations in Colorectal Cancer Patients
December 9th 2017Alan P. Venook, MD, recently discussed 2 cases of patients with colorectal cancer, and the treatment treatment considerations and decisions he would make when treating these patients. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, and professor, Department of Medicine, University of California San Francisco, discussed these cases during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.<br />
Read More
Expert Details Promising New Therapies on the Horizon for BRAF-Mutant CRC
December 1st 2017Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) CRC and highlights some of the identified molecular mutations in patients with CRC.
Read More
Guidelines Consider Use of Targeted Therapies in Colorectal Cancer
November 30th 2017The use of targeted therapies in colon cancer has become increasingly important, with several options available for clinicans to choose between. In a review of recent updates incorporating molecularly targeted therapy use in the National Comprehensive Cancer Network guidelines, the evidence for these new recommendations are detailed in support of their use in patients with colon cancer.
Read More
Choosing Between TAS-102 and Regorafenib in Colorectal Cancer
November 30th 2017Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.
Watch
Avelumab Fails to Improve OS in Phase III Gastric Cancer Trial
November 30th 2017In findings from the phase III JAVELIN Gastric 300 trial, survival was not improved with the anti–PD-L1 agent avelumab compared with chemotherapy in previously treated patients with gastric or gastroesophageal junction adenocarcinoma.<br />
Read More
Lower-Dose Sorafenib Leads to Reduction in Discontinuation Rate for HCC Patients
November 30th 2017In patients with hepatocellular carcinoma (HCC), pill burden and treatment costs were reduced, with a trend toward improved treatment completion, by lowering the dose of sorafenib (Nexavar), according to results from a retrospective, multi-institutional study.
Read More
Decision Making in the Frontline Treatment of Metastatic Colon Cancer
November 29th 2017John L. Marshall, MD, Director, The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, discusses decision making in the frontline treatment of patients with metastatic colon cancer.
Watch
Kim Explains Metastatic Colorectal Cancer Treatment Considerations in 2 Patient Cases
November 17th 2017Richard Kim, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer, including the role of mutation testing and location of the tumor. Kim, associate professor of oncology, Moffitt Cancer Center, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Identifying Unique Antigen Qualities in Long-Term Pancreatic Cancer Survivors
November 16th 2017Vinod P. Balachandran, MD, Surgical Oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis to determine the unique antigen qualities of long-term survivors of pancreatic cancer during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Watch